Pfizer is set to provide its earnings report for the first quarter of 2017 before the market opens today. The pharmaceutical giant has scheduled a conference call with the selected investment analyst at 10 a.m. to provide an update on Pfizer’s results, as reflected in the company’s performance report. Let’s see what we can expect from Pfizer in the quarter ending in March.
Pfizer Inc. received a consensus EPS estimate of $0.67 for the quarter, similar with the EPS recorded in the same quarter last year and higher compared to the $0.47 EPS in the quarter ended on December 2016.
The largest US pharmaceutical company, with a current market capitalization of $201.52 billion, is expected to deliver $13.1 billion for the quarter, lower than the reported $13.6 Billion from the preceding quarter. Speculators are looking at the possibility of the negative impact brought by Pfizer’s mature drug portfolio in the middle of the tight competition in the drug industry.
For the entire year, Pfizer is anticipating revenue to reach $52.0 to $54.0 billion. Chairman and Chief Executive Officer Ian Read indicated in his statement during the fourth quarter call in 2016 that they are positioned for a strong performance in 2017.
“We are operating with a highly focused business structure and management team, providing us with the best opportunity to generate attractive operating revenue and earnings growth as demonstrated by our 2017 financial guidance. Our strong in-market product portfolio and broad R&D pipeline include several potential first-in-class or best-in-class compounds in important therapeutic areas,” Read explained.
The first quarter results will definitely dictate the tone to the attainment of its primary goals for 2017.
In-line with this, the Company will probably focus on the sales of its key products - Prevnar 13, Enbrel, Lyrica, Ibrance, and Eliquis. Pfizer’s flagship vaccine Prevnar 13 may remain a little bit off after its sales declined 8 percent to $5.7 billion last year. The pneumococcal vaccine and a conjugate vaccine have contributed significantly in the total revenue of the company; however, due to fewer adult vaccinations in the first quarter, there could be negative figures.
On the other hand, the relevance of Anacor and Medivation acquisitions in the financial performance of the company will be highly expected. The sales of Ibrance and Eliquis may also provide a positive tone in the total sales of Pfizer.
As seen on the chart below, Pfizer Inc, entered 2017 steady and showed signs of regaining the momentum from the fall at the end of the December quarter. A swift slide came after; nevertheless, the green candles appeared after the earnings season.
Apparently, the stock receives attention from the investors before the financial report of the company. However, what seems to be significant here is how the stock managed to keep the momentum until the end of March 2017.
From 32.98 levels in the start of January, Pfizer Inc reached as high as 34.63 levels for the quarter. Although the numbers there was no major jump at all, it matters that there was no major plunge as well.
The stock evidently performed better in the first quarter of 2017 than in the last quarter of 2017. It could be something to consider in terms of the financial performance of the company.
Currently, Pfizer consolidated at $33.78 and emerged at $34.19 in the pre-market session. It has an intraday high of 33.99 and intraday low of 33.77. Pfizer posted a price earnings ratio of 28.97 and dividend yield of 3.79 percent.
Should the earnings result beat the market expectations, the stock will likely be going upward in the coming sessions.
More news about the market? Get it here in FSM News. FSM News gives you the most recent financial news. Subcribe Now!